Trials / Unknown
UnknownNCT04620655
RD13-01 for Patients With r/r CD7+ T-ALL/T-LBL
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 24 (estimated)
- Sponsor
- Min Xiang · Academic / Other
- Sex
- All
- Age
- 3 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed to explore the safety of RD13-01 for patients with CD7+ relapsed and/or refractory T cell acute lymphoblastic leukemia or lymphoblastic lymphoma. And to evaluate the efficacy and pharmacokinetics of RD13-01 in patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RD13-01 cell infusion | Universal CAR-T cells targeting CD7 |
Timeline
- Start date
- 2020-11-15
- Primary completion
- 2021-11-15
- Completion
- 2022-11-15
- First posted
- 2020-11-09
- Last updated
- 2020-11-09
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04620655. Inclusion in this directory is not an endorsement.